Explorez tous les épisodes du podcast Respiratory GURU: Genuinely Useful Respiratory Updates
| Titre | Date | Durée | |
|---|---|---|---|
| Respiratory GURU Series 2, Episode 5: ERJ ABPA Clinical Practice Guidelines-Treatment | 27 Aug 2024 | 00:36:18 | |
In this next episode, we return to talk to Chris about ABPA treatment, including recommendations for monitoring and treatment dependant patients. Hope this helpful, as we certainly learnt a lot! | |||
| Respiratory GURU Series 2, Episode 4: ERJ ABPA clinical practice guidelines: Diagnosis | 27 Aug 2024 | 00:33:26 | |
This podcast we discuss ABPA diagnosis including the investigations and their parameters which have recently changed. Listen when Mike and I discuss the guidelines with one of the paper's authors and get to grips with ABPA diagnosis even if those cases that are a little trickier. | |||
| Respiratory GURU Episode 7: COPD | 11 Mar 2022 | 00:45:13 | |
This month's episode is all about COPD, and I am joined by the brilliantly intelligent Professor Alice Turner. Her knowledge of the research in this field is remarkably in-depth, yet she is generous with her experience and answers the questions you want to ask but may not feel comfortable exposing the chasms in your knowledge like I did! 40 minute podcast, strap in for a detailed, transformative and revelatory podcast with an international COPD leader. | |||
| Respiratory GURU Episode 6: Lung USS and POCUS | 18 Feb 2022 | 00:33:12 | |
A vibrant discussion with Dr Sarb Clare MBE and author of Ultrasound for the Generalist about point of care lung USS and how we can use lung USS to achieve rapid diagnoses, without needing to wheel down to imaging. No more distinctly average portable CXRs, USS offer us the ability to do bedside serial imaging on our unwell respiratory patients and to see with our own eyes what is going on inside when we don't quite believe the CXR or our vocal resonance examination. | |||
| Respiratory GURU Episode 5: MDR TB | 11 Feb 2022 | 00:40:30 | |
A great discussion of the recent MDR TB Clinical Advice Service Annual Report, and a complex MDR TB case as a great demonstration of the intricacies of it's management. Dr Guy Hagan is our local TB lead and an encyclopaedia of TB treatments, and we talk about a tricky pericardial TB patient and his clinical journey. I learnt so much about the group A, B and C selection of medications for MDR TB, how to use the clinical advice service and look out for the rare side effects. | |||
| Respiratory GURU Episode 4: Review of asthma biologics in NICE and in development | 21 Jan 2022 | 00:48:55 | |
Discussion with Professor Adel Mansur who is the lead for the Birmingham Regional Asthma Service about the 4 main current biologics in the asthma NICE guidelines together with discussion of three more novel agents in development that have recently been published. A must listen for anyone reviewing asthma patients, Adel gives a great summary of the underlying mechanisms for these agents, their current use in clinical practice and importantly...how to pronounce them! Papers reviewed are as follows: | |||
| Respiratory GURU Episode 3: Summary of ERS Sarcoidosis guidelines and GINA asthma guidelines | 24 Dec 2021 | 00:19:32 | |
This Christmas present is a summary of the recently updated guidelines for Sarcoidosis and asthma. 20 minute summary of the guidelines to listen to whilst munching on a mince pie and a glass of something festive. You're welcome. | |||
| Respiratory GURU Episode 2: November updates part 1 | 06 Dec 2021 | 00:30:05 | |
November's summary of clinical respiratory updates; 30 min podcast to listen to on the way to work or any kind of multitasking so you can keep up to date without even trying. This month's papers and guidelines are: | |||
| Respiratory GURU Episode 1: Oct 2021 updates | 25 Nov 2021 | 00:52:48 | |
October's summary of clinically relevant respiratory publications released in the past month. | |||
| Respiratory GURU Series 2, episode 3: CTD ILD | 31 Jan 2024 | 00:49:17 | |
Welcome back to the next instalment of respiratory GURU, this time we delve into two RCTs investigating rescue therapy for patients with CTD ILD. The EVER ILD study looks at MMF vs MMF plus rituximab, and the RECITAL study looks at rituximab vs cyclophosphamide. 2 very useful studies and I was thrilled to be joined by two national experts in the field, Dr Anjali Crawshaw and Dr Emma Derrett-Smith. Hopefully, this will make you feel more well-prepared for ILD MDTs, and give you a real insight into how these two experts view the recent literature in the context of their day-to-day practice. Here are the pubmed links for the two papers, the INBUILD study which we discuss briefly, and the American College of Rheumatology guidelines, which apparently is where most of the guidance we need regarding CTD ILD (for now) sits. Enjoy listening, thank you for being patient with the podcast releases whilst I birthed and raised my second child, and fingers crossed no more career interruptions!! Mankikian J et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023 Jun 8;61(6):2202071. doi: 10.1183/13993003.02071-2022. PMID: 37230499. | |||
| Respiratory GURU Series 2: Episode 2 - Occupational Lung Disease | 05 Sep 2023 | 01:06:18 | |
A vibrant discussion with our two regional leads for occupational lung disease and a specialised solicitor dealing with OLD claims into how to drill down into the details of an occupational lung disease, how to refer, how to write your clinical letters and how to direct patients towards compensation if it's right for them. | |||
| Respiratory GURU Series 2: Episode 1 - COPD | 05 Aug 2023 | 01:03:10 | |
A perfect introduction to series 2, a COPD podcast with Professor Turner and Dr LJ Smith where we jump into MART for COPD, the new P2X3 receptor agonist Filapixant, antihyperglycaemic drugs preventing COPD exacerbations and much more. Happy listening! | |||
| Respiratory GURU Episode 12: Complex breathlessness | 02 Nov 2022 | 00:50:59 | |
This fascinating episode delivers pragmatic advice and recommendations for how to identify and manage patients with inducible laryngeal obstruction (ILO)-the new phrase for vocal cord dysfunction, GORD and breathing pattern disorders-the new phrase for dysfunctional breathing. This will make so much difference to how you do your consults with your breathless patients who have one of these disorders, how to reassure them, treat them and not feel a deep heart sink when you read your last letter about them before calling them into your consultation room. The quality of this podcast recording is not at the highest standard I strive to achieve, so bear with me, and turn up the volume a little when prof is speaking, you won't want to miss a word! | |||
| Respiratory GURU Episode 11: Aspergillosis Part 2 (CPA and invasive aspergillosis) | 06 Oct 2022 | 00:40:39 | |
Next instalment of the aspergillosis podcast, where we move on to talk about chronic pulmonary aspergillosis and invasive aspergillosis. Hope you've had time to digest part 1, part 2 is filled with useful content about diagnostics again, including the utility or lack of as it might be of galactomannans and Beta D Glucans in aspergillosis. Thank you again to Dr Chris Kosmidis. | |||
| Respiratory GURU Episode 10: Aspergillosis Part 1 (ABPA) | 05 Oct 2022 | 00:29:09 | |
An interview with Dr Chris Kosmidis, Clinical Senior Lecturer at Wythenshawe Hospital and Aspergillosis centre about aspergillosis. Divided into two parts, the first part of our discussion covers ABPA for the generalist, and is a goldmine of information for diagnosing, treating and monitoring response in these patients. I now feel comfortable interpreting the serology, prescribing antifungals where appropriate and how to look out for a relapse which is a long way from where I started! | |||
| Respiratory GURU Episode 9: Interstitial Lung Disease | 25 Jul 2022 | 00:46:01 | |
This month's episode dives into progressive fibrosing ILD, previously a disadvantaged set of patients who have a progressive ILD but as they weren't specifically UIP they were not entitled to antifibrotic treatment. So thank goodness for the INBUILD trial back in 2020 and it's extension and NICE technological appraisal for injecting pragmastism not only in to the types of patients now referrable for antifibrotics, but also the referral criteria. This has moved away from FVC and towards radiological classification and gas transfer which we all know are useful parameters of parenchymal health. We also talk about post COVID fibrosis, anti-reflux medication and anti-cough medication. I am joined by two regional experts in the field, Dr Chris Huntley and Dr Gareth Walters. References are below: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials PMID: 21571362 A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis DOI: 10.1056/NEJMoa1402582 Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis DOI: 10.1056/NEJMoa1402584 Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis DOI: 10.1056/NEJMoa1103690 Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial PMID: 33798455 Nintedanib in Progressive Fibrosing Interstitial Lung Diseases DOI: 10.1056/NEJMoa1908681 Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) PMID: 35050837 Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PMID: 34795926 Post COVID PFT and CT systematic review: PMID: 35642193 | |||
| Respiratory GURU Episode 8: Pleural disease | 26 May 2022 | 00:57:14 | |
Finally it's here, the pleural podcast! Ever wondered why you can't get a straight answer about suction, talc and fibrinolytics? That's because the evidence until recently has been poor and we're still using guidelines written 12 years ago. But with the assistance of two excellent pleural specialists we pull apart the latest studies to discuss all your usual pleural conundrums to help you manage 90% of pleural disease within your local hospital, minimise the time spent in a hospital bed and reduce the need for a surgeon getting involved.
Conservative versus Interventional Treatment for Spontaneous Pneumothorax: PMID: 31995686
Ambulant treatment with a digital chest tube for prolonged air leak is safe and effective: PMID: 35070365
The Impact of Gravity vs Suction-driven Therapeutic Thoracentesis on Pressure-related Complications: The GRAVITAS Multicenter Randomized Controlled Trial: PMID: 31711990
Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial PMID: 35081010
Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial PMID: 29225889
Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial PMID: 31804680
The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing DOI:https://doi.org/10.1016/S2666-5247(21)00327-X | |||